Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma
Mezigdomide led to 41% response rate in heavily pretreated patients
Source: medpagetoday.com
Jake Shortt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jake Shortt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jake Shortt Today - Breaking & Trending Today
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory peripheral T cell lymphoma is accepted as a poster presentationA trial in progress abstract of the... | May 11, 2023
Source: marketscreener.com
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy
Source: finanznachrichten.de